CSPC Recomgen Pharmaceutical

CSPC Recomgen Pharmaceutical is a specialized biotechnology subsidiary of the CSPC Pharmaceutical Group, focused on the development and large-scale production of recombinant protein therapeutics and vaccines. Headquartered in Guangzhou, China, the company operates a state-of-the-art manufacturing base that includes one of the world's largest production lines for recombinant human serum albumin (rHSA). Its clinical pipeline is highlighted by TG103, a long-acting recombinant GLP-1 receptor agonist currently in Phase 3 trials for obesity and type 2 diabetes. The company leverages advanced yeast-based expression systems and high-efficiency purification technologies to create high-purity biological products. As a key component of CSPC's biologics strategy, Recomgen aims to address critical shortages in plasma-derived products and provide innovative treatments for metabolic and inflammatory diseases.